Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report 2021 - 2028
Inflammatory Bowel Disease Treatment Industry Overview
The global inflammatory bowel disease treatment market size was valued at USD 19.2 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 4.8% from 2021 to 2028. The rising prevalence of Crohn’s disease and ulcerative disease across the globe is expected to drive market growth over the forecast period. Moreover, increasing adoption of biologics for the treatment and the presence of strong pipeline drugs such as upadacitinib, risankizumab, tofacitinib, ustekinumab, and others is anticipated to boost the market growth in the coming years. The impact of the COVID-19 pandemic on the market was negligible in 2020 whereas, a downfall in the diagnosis of inflammatory bowel disease has been observed in many countries due to the complete lockdown imposed in those countries.
The increasing prevalence of Crohn’s disease and ulcerative colitis is one of the key factors expected to drive the market for inflammatory bowel disease treatment. According to the Crohn’s and Colitis Foundation (CCFA), around 70,000 new cases of inflammatory bowel disease are diagnosed in the U.S. every year. As per the CCFA report of 2019, about 1.6 million people were living with Inflammatory Bowel Disease in the U.S. Moreover, according to the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA), there were around 3.4 million people in Europe living with any form of IBD in 2020. An increasing number of people are being affected by IBD thereby increasing the demand for effective treatment options.
Gather more insights about the market drivers, restrains and growth of the Global Inflammatory Bowel Disease Treatment market
The presence of strong pipeline products for the treatment of Inflammatory Bowel Disease (IBD) is going to drive market growth. According to the U.S. National Library of Medicine, as of October 2019, there are a total of 730 clinical trials (includes drug development, observational studies, and others) related to IBD, and out of these 268 clinical trials are being conducted in the United States only. In the drug development against the inflammatory bowel disease segment, there are 63 clinical trials in phase-1, 132 clinical trials in phase-2, and 101 clinical trials in phase-3 globally. For instance, AbbVie Inc.’s Rinvoq (upadacitinib), a JAK inhibitor, is a promising drug candidate under phase 3 clinical trial for the treatment of Crohn's disease and ulcerative colitis. Companies are engaged in the development of JAK inhibitors, anti-interleukin, S1P modulators, and other biologics to treat IBD.
Increasing approval of biosimilars such as Hyrimoz, Imraldi, Renflexis, and Inflectra is expected to increase the adoption of effective treatment due to its advantages over traditional treatment options. Other biosimilar products like Cyltezo (Boehringer Ingelheim), Hulio (Mylan N.V.), Avsola (Amgen Inc.), IXIFI (Pfizer Inc.) have received approval and are expected to be commercialized in near future. The launch of biosimilars is expected to increase the demand from emerging markets as these markets are price sensitive. Also, the increasing approval of biosimilars for pediatric Crohn’s disease will contribute to market growth globally.
Browse through Grand View Research's Pharmaceuticals Industry Research Reports.
- Sarcoma Drugs Market - The global sarcoma drugs market size was valued at $703 million in 2017. It is expected to register a CAGR of 8.5% during the forecast period. Soaring adoption of novel drugs, the presence of strong developmental pipeline, rising incidence of soft tissue sarcomas (STS), and increasing R&D activities are some of the key trends stoking market growth.
- Hyperlipidemia Drugs Market - The global hyperlipidemia drugs market size was valued at USD 19.3 billion in 2016. It is estimated to progress at a CAGR of 2.3% over the forecast period. Introduction of new guidelines that redefined at-risk patient groups and the emergence of novel drug classes promising better efficacy and safety levels are among the key factors stoking market growth. Hyperlipidemia is caused by an elevation in blood lipid levels and can be classified into two types - primary and secondary.
Inflammatory Bowel Disease Treatment Market Segmentation
Grand View Research has segmented the global inflammatory bowel disease treatment market on the basis of type, drug class, route of administration, distribution channel, and region:
Inflammatory Bowel Disease Treatment Type Outlook (Revenue, USD Million, 2017 - 2028)
- Crohn's Disease
- Ulcerative Colitis
Inflammatory Bowel Disease Treatment Drug Class Outlook (Revenue, USD Million, 2017 - 2028)
- Aminosalicylates
- Corticosteroids
- TNF inhibitors
- IL inhibitors
- Anti-integrin
- JAK inhibitors
- Others
Inflammatory Bowel Disease Treatment Route of Administration Outlook (Revenue, USD Million, 2017 - 2028)
- Oral
- Injectable
Inflammatory Bowel Disease Treatment Distribution Channel Outlook (Revenue, USD Million, 2017 - 2028)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Inflammatory Bowel Disease Treatment Regional Outlook (Revenue, USD Million, 2017 - 2028)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa (MEA)
Key Companies profiled:
Some prominent players in the global Inflammatory Bowel Disease Treatment market include
- AbbVie Inc.
- Biogen
- Johnson & Johnson Services, Inc.
- Amgen Inc.
- UCB S.A.
- Novartis AG
- Takeda Pharmaceutical Company Limited
- Merck & Co., Inc.
- Pfizer Inc.
- Lilly
Order a free sample PDF of the Inflammatory Bowel Disease Treatment Market Intelligence Study, published by Grand View Research.
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Comments
Post a Comment